Immunologic therapy targeting metastatic melanoma: allovectin-7 - PubMed (original) (raw)
Immunologic therapy targeting metastatic melanoma: allovectin-7
Rozina Chowdhery et al. Immunotherapy. 2011 Jan.
Abstract
In the USA, the incidence of cutaneous melanoma is increasing rapidly. It has been shown to be responsive to immune-stimulating drugs. Allovectin-7 allows the immune system to recognize metastatic melanoma lesions as foreign by incorporating a MHC class I complex into the tumor through direct injection. Once transfected, tumor biopsies have shown an increased presence of cytotoxic T lymphocytes in the tumor beds themselves. Phase I and II trials have shown local and systemic response to these tumors, with an excellent safety profile. Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy.
Similar articles
- Allovectin-7 therapy in metastatic melanoma.
Bedikian AY, Del Vecchio M. Bedikian AY, et al. Expert Opin Biol Ther. 2008 Jun;8(6):839-44. doi: 10.1517/14712598.8.6.839. Expert Opin Biol Ther. 2008. PMID: 18476795 Review. - Velimogene aliplasmid.
Soares HP, Lutzky J. Soares HP, et al. Expert Opin Biol Ther. 2010 May;10(5):841-51. doi: 10.1517/14712598.2010.481280. Expert Opin Biol Ther. 2010. PMID: 20367461 Review. - Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. Stopeck AT, et al. Clin Cancer Res. 2001 Aug;7(8):2285-91. Clin Cancer Res. 2001. PMID: 11489803 Clinical Trial. - Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions.
Rini BI, Selk LM, Vogelzang NJ. Rini BI, et al. Clin Cancer Res. 1999 Oct;5(10):2766-72. Clin Cancer Res. 1999. PMID: 10537340 Clinical Trial. - Technology evaluation: Allovectin-7, Vical.
Galanis E. Galanis E. Curr Opin Mol Ther. 2002 Feb;4(1):80-7. Curr Opin Mol Ther. 2002. PMID: 11883699 Review.
Cited by
- Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.
Kraft JC, Freeling JP, Wang Z, Ho RJ. Kraft JC, et al. J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25. J Pharm Sci. 2014. PMID: 24338748 Free PMC article. Review. - Current treatment of locoregional recurrence of melanoma.
Squires MH 3rd, Delman KA. Squires MH 3rd, et al. Curr Oncol Rep. 2013 Oct;15(5):465-72. doi: 10.1007/s11912-013-0333-5. Curr Oncol Rep. 2013. PMID: 23907518 Review. - Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
Doukas J, Rolland A. Doukas J, et al. Cancer Gene Ther. 2012 Dec;19(12):811-7. doi: 10.1038/cgt.2012.69. Epub 2012 Oct 5. Cancer Gene Ther. 2012. PMID: 23037806 Free PMC article. Review. - Cell cycle gene networks are associated with melanoma prognosis.
Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG. Wang L, et al. PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536322 Free PMC article. - Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
Hartikka J, Bozoukova V, Morrow J, Rusalov D, Shlapobersky M, Wei Q, Boutsaboualoy S, Ye M, Wloch MK, Doukas J, Sullivan S, Rolland A, Smith LR. Hartikka J, et al. Hum Vaccin Immunother. 2012 Nov 1;8(11):1595-606. doi: 10.4161/hv.21225. Epub 2012 Aug 24. Hum Vaccin Immunother. 2012. PMID: 22922766 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials